Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.
The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to major depressive disorder.
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Update
Dr Steven Gourlay
CEO and MD
Michael Roberts
Head of investor relations
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 51.9 | 45.9 | 5.6 |
Relative | 51.4 | 46.1 | (4.4) |
52 week high/low | A$0.0/A$0.0 |
Actinogen Medical’s lead asset, Xanamem, is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood-brain barrier and target excess brain cortisol, which has been associated with CI. The company is targeting two CI indications: for patients with mild CI in the early stages of Alzheimer’s disease (AD) and for patients with major depressive disorder. Positive results in healthy adults demonstrated the drug’s initial efficacy, while an analysis of biomarker-positive (pTau-181) patients using plasma samples from the previous XanADu study in mild AD also showed clinical activity using the CDR-SB scale, as published in the June 2024 issue of the Journal of Alzheimer’s Disease. Actinogen dosed the first patient in its Phase IIb XanaMIA trial in patients with biomarker-confirmed early AD in April 2024, and plans to report interim data in mid CY25. It expects to report data from the XanaCIDD Phase II trial in major depressive disorder in early Q3 CY24.
Y/E Jun | Revenue (A$m) | EBITDA (A$m) | PBT (A$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 3.6 | (9.1) | (7.9) | (0.460) | N/A | N/A |
2023A | 4.9 | (10.6) | (8.9) | (0.494) | N/A | N/A |
2024E | 7.9 | (14.7) | (14.0) | (0.621) | N/A | N/A |
2025E | 7.7 | (14.0) | (13.7) | (0.512) | N/A | N/A |